Collectively, these data provide evidence that FOXO3 is methylated in basal subtype breast cancers, where BRCA1 is either mutated or depleted, highlighting the importance of BRCA1 in promoting FOXO3 expression through suppressing FOXO3 methylation in luminal breast cancers. The gene discussed is FOXO3; the disease is breast carcinoma.